Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.57 |
| ▸ | JAK1 | P23458 | 6/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.50 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 6/20 | 0.48 |
| ▸ | CDK1 | P06493 | 5/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.48 |
| ▸ | CDK9 | P50750 | 3/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CCND3 | P30281 | 1/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 6/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974490 | 0.99 | JAK3 (0.58) | JAK3JAK1NTRK1BTKEGFR | |
| SCHEMBL4972992 | 0.96 | JAK3 (0.60) | JAK3JAK1NTRK1BTKEGFR | |
| SCHEMBL4973704 | 0.91 | AURKA (0.52) | JAK3JAK1NTRK1CDK2CDK1 | |
| SCHEMBL4975196 | 0.90 | AURKA (0.53) | JAK3JAK1NTRK1CDK2CDK1 | |
| SCHEMBL4973463 | 0.90 | JAK3 (0.59) | JAK3JAK1NTRK1BTKEGFR | |
| SCHEMBL4972312 | 0.88 | JAK3 (0.49) | JAK3JAK1NTRK1BTKEGFR | |
| SCHEMBL4972409 | 0.87 | NTRK1 (0.55) | JAK3JAK1NTRK1BTKEGFR | |
| SCHEMBL4971338 | 0.87 | AURKA (0.55) | JAK3JAK1NTRK1CDK2CDK1 | |
| SCHEMBL4973116 | 0.87 | SYK (0.57) | JAK3JAK1NTRK1EGFRCDK2 | |
| SCHEMBL4973502 | 0.86 | SYK (0.57) | JAK3JAK1NTRK1EGFRCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991532-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | claimed |
| US-8962643-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | claimed |
| EP-1991532-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2007098507-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
| EP-1991532-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9481654-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150158824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-8962643-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-1991532-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007098507-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885NTRK1 4560/4885 |
| US-20150158824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885NTRK1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.